View all newsletters
Receive our newsletter - data, insights and analysis delivered to you

What is a Biosimilar and How Does it Differ Compared to Drug Development?

Prior to March 23 2010, there was no regulatory pathway for biosimilar development in the US.

It was then that the President signed the Biologics Price Competition and Innovation Act of 2009 (BPCI Act) into law, which amended the Public Health Service Act (PHS Act) and created an abbreviated review pathway for US biosimilars.

Although the pathway is abbreviated, similarities to the Reference Product must be proven with rigorous data and the guidelines are stringent. Biosimilar sponsors must demonstrate that the proposed compound is highly similar (biosimilar) to or interchangeable with the Reference Product.

Not surprisingly, the first biosimilar was not approved in the US until 2015. This brief description of biosimilars illustrates a variety of the challenges to consider as you contemplate your next development project.

Click here to read more.

Clinical trial consulting and pharmaceutical consulting professionals will benefit by becoming current on adaptive trial design.
Safety surveillance and pharmacovigilance consulting to generic drug manufacturers, as well as generic drug labelling consulting may soon become a service in demand.
Pharmaceutical Development Group (PDG) is a drug and medical device consultant that continuously engages in meetings and interactions with the US Food and Drug Administration...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology